Chronic bronchitis
Drug research and approvals for chronic bronchitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 100 studies of chronic bronchitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 100
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis…NCT07771855 · Phase 2 · Hopital Foch · starts Jun 24, 2026
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged…NCT07771439 · Phase 3 · Sanofi · starts Oct 12, 2026
- A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease…NCT07759245 · Phase 2 · Eli Lilly and Company · starts Aug 7, 2026
- Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host DiseaseNCT07733141 · Not applicable · City of Hope Medical Center · starts Mar 1, 2027
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With…NCT07725939 · Phase 2 · UCB Biopharma SRL · starts Jul 27, 2026
- Dry Dynamic Cupping vs Instrument-Assisted Soft Tissue Mobilization for Chronic Myofascial Low Back PainNCT07685340 · Not applicable · Ibadat International University, Islamabad · starts Jan 1, 2026
- To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of TreatmentNCT07684820 · Phase 2 · Expedition Therapeutics, Inc · starts Jun 30, 2026
- Study of AHB-171 in Chronic Hepatitis B ParticipantsNCT07630727 · Phase 2 · Ausper Biopharma Co., Ltd. · starts Jun 24, 2026
- A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCTNCT07606703 · Phase 2 · WeiShi · starts Sep 1, 2025
Approved 24 of 29
- AzithromycinBacterial 70S ribosome inhibitor
- LevofloxacinDNA gyrase inhibitor
- TelithromycinBacterial 70S ribosome inhibitor
- MoxifloxacinTopoisomerase IV inhibitor
- SalmeterolBeta-2 adrenergic receptor agonist
- Fluticasone propionateGlucocorticoid receptor agonist
- RoflumilastPhosphodiesterase 4 inhibitor
- TiotropiumMuscarinic acetylcholine receptor M3 antagonist
- ArformoterolBeta-2 adrenergic receptor agonist
- FormoterolBeta-2 adrenergic receptor agonist
- CefdinirBacterial penicillin-binding protein inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- CiprofloxacinBacterial DNA gyrase inhibitor
- OfloxacinBacterial DNA gyrase inhibitor
- BudesonideGlucocorticoid receptor agonist
- AclidiniumMuscarinic acetylcholine receptor M3 antagonist
- IpratropiumMuscarinic acetylcholine receptor M3 antagonist
- GlycopyrroniumMuscarinic acetylcholine receptor M3 antagonist
- TheophyllinePhosphodiesterase 4 inhibitor
- VilanterolBeta-2 adrenergic receptor agonist
- IndacaterolBeta-2 adrenergic receptor agonist
- CefaclorBacterial penicillin-binding protein inhibitor
- Cefuroxime axetilBacterial penicillin-binding protein inhibitor
- Cefprozil anhydrous, (e)-Bacterial penicillin-binding protein inhibitor
Phase 3 4
- AmoxicillinBacterial penicillin-binding protein inhibitor
- Clavulanic acidBacterial beta-lactamase TEM inhibitor
- PrulifloxacinBacterial DNA gyrase inhibitor
- Faropenem medoxomilBacterial penicillin-binding protein inhibitor
Phase 2 6
- IvacaftorCystic fibrosis transmembrane conductance regulator positive modulator
- ABX-IL8Interleukin-8 inhibitor
- AcetylcysteineGlutathione precursor
- ErdosteineExpectorant
- CofirasersenAmiloride-sensitive sodium channel, ENaC mRNA antisense inhibitor
- Tozorakimab
How its trials ended
149 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 40 whose ending is known, 35% met their primary endpoint, 13% missed it and 53% stopped early.
- Completed, result not reported7450%
- Status unknown1812%
- Ongoing1711%
- Stopped: other or unclear1711%
- Met its primary endpoint149%
- Missed its primary endpoint53%
- Stopped: enrollment or feasibility21%
- Stopped: lack of efficacy11%
- Stopped: sponsor or business decision11%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jul 5, 2010 | DaxasRoflumilast | AstraZeneca AB | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA